Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32665598 | 0.93 | NPC1 (0.46) | GLAL3MBTL1NPC1RAB9AKMT2A | |
| SCHEMBL32665453 | 0.91 | NPC1 (0.48) | NPC1RAB9APOLBKMT2AALDH1A1 | |
| SCHEMBL32665073 | 0.89 | CA2 (0.43) | GLAL3MBTL1NPC1RAB9AALDH1A1 | |
| SCHEMBL32665109 | 0.85 | CYP2C9 (0.44) | L3MBTL1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL31138818 | 0.79 | CD274 (0.52) | NPC1RAB9APOLBMEN1KMT2A | |
| SCHEMBL9610832 | 0.79 | CD274 (0.52) | NPC1RAB9APOLBMEN1KMT2A | |
| SCHEMBL32665266 | 0.79 | LMNA (0.46) | L3MBTL1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL32665168 | 0.78 | DRD2 (0.44) | MEN1KMT2AGAAMAPT | |
| SCHEMBL32665265 | 0.78 | OPRM1 (0.50) | NPC1RAB9AMEN1KMT2AGAA | |
| SCHEMBL15393707 | 0.77 | KMT2A (0.61) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | GLA 3982/4885L3MBTL1 675/4885NPC1 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.